Stay updated on BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial
Sign up to get notified when there's something new on the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page.

Latest updates to the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page
- Check6 days agoChange DetectedThe page continues to display a 403 Forbidden error. The footer revision identifier changes from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedA site-wide NIH banner announces a transition from “Artificial Intelligence” to “Super Intelligence” terminology. The site revision advances from v3.7.1 to v3.7.2.SummaryDifference1%

- Check34 days agoChange DetectedThe ClinicalTrials.gov page remains a 403 Forbidden error page, with the displayed site revision updated from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check48 days agoChange DetectedThe study page now displays a 403 Forbidden error, replacing the study details with an access-denied screen.SummaryDifference17%

- Check55 days agoChange DetectedRevision updated from v3.6.6 to v3.7.0, indicating a newer page version. This change appears to be a non-content update to the page's template or formatting rather than any study details.SummaryDifference0.1%

- Check69 days agoChange DetectedThe page revision tag was updated to v3.6.6, replacing the previous v3.6.5 on the study record.SummaryDifference0.1%

Stay in the know with updates to BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page.